Navigation Links
BioCryst Presents Phase I Peramivir Data at the Options for the,Control of Influenza Conference

Pharmacokinetic and Safety Profile of the Intramuscular Formulation of Peramivir Supports Further Evaluation as Treatment for Acute Influenza

BIRMINGHAM, Ala., June 18, 2007 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. presented results from two Phase I clinical studies of an intramuscular (i.m.) formulation of peramivir at the Options for the Control of Influenza Conference in Toronto, Ontario, Canada. This major international influenza conference is held only once every four years.

These studies represent an important component of the company's clinical development program for peramivir, a neuraminidase inhibitor being developed for the treatment of seasonal and potentially life-threatening influenza. Top-line data are summarized as follows:

    -- A total of 51 healthy adult volunteers received either one of three

       dose regimens of peramivir or placebo

    -- Maximum plasma concentrations of peramivir (ranging from approximately

       4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after

       administration

    -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours)

    -- The bioavailability of single doses of i.m. peramivir is high (>98%)

    -- Peramivir was well-tolerated in both of these studies

Jon P. Stonehouse, Chief Executive Officer of BioCryst said "these findings suggest an excellent safety profile of peramivir when given as an intramuscular injection, and, secondly, the concentrations of peramivir in blood after intramuscular dosing are reassuringly high and are similar to levels after intravenous administration. We look forward to the completion of our ongoing Phase II study of i.m. peramivir in the treatment of acute influenza in outpatients."

BioCryst is advancing the clinical development of peramivir under terms of a contract from the U.S. Department of Health and Human Services (DHHS) which on Janu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
Post Your Comments:
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... preliminary financial results for the first quarter of ... Ended September 30, 2014 Financial Highlights: , ... in 1Q14 with gross margins improved to 52% ...
(Date:12/24/2014)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... that address unmet medical needs in the areas ... on December 24, 2014 it closed its previously ... raised approximately $2.3 million in gross proceeds from ... proceeds from the offering to fund its research ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... China , May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... and distributor in China of glucose and starch ... its financial results for the third quarter and the first ... . , , Financial Summary of the ...
... China , May 17 /PRNewswire-Asia-FirstCall/ -- ... Biologic" or the "Company"), one of the,leading plasma-based ... ("PRC"), operating through its indirect majority-owned subsidiaries,Shandong ... Dalin,Biologic Technologies Co., Ltd. ("Dalin") and its equity ...
Cached Medicine Technology:Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 2Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 3Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 4Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 5Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 6Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010 7China Biologic Products Announces First Quarter 2010 Results 2China Biologic Products Announces First Quarter 2010 Results 3China Biologic Products Announces First Quarter 2010 Results 4China Biologic Products Announces First Quarter 2010 Results 5China Biologic Products Announces First Quarter 2010 Results 6China Biologic Products Announces First Quarter 2010 Results 7China Biologic Products Announces First Quarter 2010 Results 8China Biologic Products Announces First Quarter 2010 Results 9China Biologic Products Announces First Quarter 2010 Results 10China Biologic Products Announces First Quarter 2010 Results 11China Biologic Products Announces First Quarter 2010 Results 12China Biologic Products Announces First Quarter 2010 Results 13China Biologic Products Announces First Quarter 2010 Results 14China Biologic Products Announces First Quarter 2010 Results 15China Biologic Products Announces First Quarter 2010 Results 16China Biologic Products Announces First Quarter 2010 Results 17China Biologic Products Announces First Quarter 2010 Results 18
(Date:12/25/2014)... December 25, 2014 When head lice hits ... in a frenzy to get rid of it while keeping ... in Coral Gables now have the solution right in their ... clinic location, Lice Troopers provides full spectrum head lice screening ... Gable area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... can receive effective, less expensive care from a clinic that ... team of dedicated health care professionals, a new study shows. ... need either hospitalization or a trip to the emergency room ... at the University of Texas in Houston versus usual care, ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... could be closing in on a "fountain of youth" drug ... health of older adults, a new study suggests. Seniors ... a drug that targets a genetic signaling pathway linked to ... report. The experimental medication, a version of ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Thousands of ... move forward in a number of multidistrict litigations currently ... Virginia, Bernstein Liebhard LLP reports. According to an Order ... to convene a Joint Status Conference in all of ... Parties have been directed to submit a proposed agenda ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4
... , ... has established a strong link between elevated commitment among employees and positive business outcomes. ... Charlotte, NC ... host a webinar titled “Building Workforce Commitment.” The free hour-long webinar will be ...
... ... clients, connecting them with the best-in-class partners around the world, delivering the ultimate experience ... ... a different connotation today than the decades old call center depiction. Clients today ...
... Hospitals ... use” of certified Electronic Medical Record (EMR) systems under the American Recovery and Reinvestment ... ... (ARRA) hospitals and physicians can receive $19 billion in subsidies over five years for ...
... ... SEO firm in 2001 under the name of Anna Tulchinsky Web Consultancy, Joomla Bliss was ... quality or professionalism. The firm is offering several website design + SEO packages tailored specifically ... , ...
... , ... on Interferential mode, is reducing the severity, duration and frequency of pain for many patients ... weeks between treatments. , ... March 9, 2010 -- The Infrex Plus Unit from MedFaxx, when used on Interferential Mode, ...
... ... ... , ... ...
Cached Medicine News:Health News:Morehead Webinar to Discuss Building Workforce Commitment 2Health News:Announcing the Evolution of Provider Placement Methodology – EPIC Connections 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 2Health News:Three Security Firms Create Consortium To Automate Meaningful Use Requirements And Qualify Clients For $Billions In Stimulus Funds 3Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 2Health News:Recession Buster for Small Businesses: Website Design and Search Engine Optimization on a Shoestring 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 2Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 3Health News:The Infrex Plus is Revolutionizing Pain Control by Stopping Pain & Eliminating Drugs for Chronic Pain Patients Who Suffered For Years 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 2Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 3Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 4Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 5Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 6Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 7Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 8Health News:New Report Says Hispanics Are One and One-Half Times More Likely to Have Alzheimer's Disease and Dementia Than Whites 9
Small size means convenient set up in any cath lab. ,System so versatile it can be mounted on I.V. pole or bedside, or bagged in sterile field....
... Used for vascular access. Hollow ... single wall puncture with two-part ... is visualized while maintaining thumb ... exits the hub of the ...
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Medicine Products: